The ever-increasing importance of cancer as a leading cause of premature death worldwide.

Published on Aug 15, 2021in Cancer5.742
· DOI :10.1002/CNCR.33587
Freddie Bray119
Estimated H-index: 119
(IARC: International Agency for Research on Cancer),
Mathieu Laversanne19
Estimated H-index: 19
(IARC: International Agency for Research on Cancer)
+ 1 AuthorsIsabelle Soerjomataram50
Estimated H-index: 50
(IARC: International Agency for Research on Cancer)
The relative importance of cardiovascular disease (CVD) and cancer as leading causes of premature death are examined in this communication. CVD and cancer are now the leading causes in 127 countries, with CVD leading in 70 countries (including Brazil and India) and cancer leading in 57 countries (including China). Such observations can be seen as part of a late phase of an epidemiologic transition, taking place in the second half of the 20th century and the first half of the present one, in which the dominance of infectious diseases is progressively superseded by noncommunicable diseases. According to present ranks and recent trends, cancer may surpass CVD as the leading cause of premature death in most countries over the course of this century. Clearly, governments must factor in these transitions in developing cancer policies for the local disease profile.
📖 Papers frequently viewed together
268 Citations
51 Citations
1 Author (Gearge Saade)
#1James E. BennettH-Index: 29
#2Vasilis KontisH-Index: 14
Last. Majid EzzatiH-Index: 138
view all 16 authors...
Summary The Sustainable Development Goal (SDG) target 3.4 is to reduce premature mortality from non-communicable diseases (NCDs) by a third by 2030 relative to 2015 levels, and to promote mental health and wellbeing. We used data on cause-specific mortality to characterise the risk and trends in NCD mortality in each country and evaluate combinations of reductions in NCD causes of death that can achieve SDG target 3.4. Among NCDs, ischaemic heart disease is responsible for the highest risk of pr...
43 CitationsSource
#1Andrew OarH-Index: 4
#2Fabio Y. Moraes (Queen's University)H-Index: 12
Last. Mei Ling YapH-Index: 13
view all 5 authors...
Summary When developed and implemented effectively, national cancer control plans (NCCPs) improve cancer outcomes at the population level. However, many countries do not have a high-quality, operational NCCP, contributing to disparate cancer outcomes globally. Until now, a standard reference of NCCP core elements has not been available to guide development and evaluation across diverse countries and contexts. In this Policy Review, we describe the methods, process, and outcome of an initiative t...
14 CitationsSource
#1Yannick Romero (Union for International Cancer Control)H-Index: 2
#2Dario Trapani (WHO: World Health Organization)H-Index: 16
Last. André Ilbawi (WHO: World Health Organization)H-Index: 11
view all 10 authors...
Summary There is increasing global recognition that national cancer plans are crucial to effectively address the cancer burden and to prioritise and coordinate programmes. We did a global analysis of available national cancer-related health plans using a standardised assessment questionnaire to assess their inclusion of elements that characterise an effective cancer plan and, thereby, improve understanding of the strengths and limitations of existing plans. The results show progress in the devel...
43 CitationsSource
#1Hellen Gelband (Center for Disease Dynamics, Economics & Policy)H-Index: 14
#2Rengaswamy Sankaranarayanan (IARC: International Agency for Research on Cancer)H-Index: 89
Last. Prabhat Jha (U of T: University of Toronto)H-Index: 71
view all 20 authors...
Summary Investments in cancer control—prevention, detection, diagnosis, surgery, other treatment, and palliative care—are increasingly needed in low-income and particularly in middle-income countries, where most of the world's cancer deaths occur without treatment or palliation. To help countries expand locally appropriate services, Cancer (the third volume of nine in Disease Control Priorities , 3rd edition) developed an essential package of potentially cost-effective measures for countries to ...
105 CitationsSource
#1Freddie BrayH-Index: 119
64 CitationsSource
#1Fabio Levi (UNIL: University of Lausanne)H-Index: 60
#2F. Lucchini (UNIL: University of Lausanne)H-Index: 30
Last. C. La Vecchia (University of Milan)H-Index: 140
view all 5 authors...
Abstract Mortality data, abstracted from the WHO database, are presented in tabular form for 26 cancer sites or groups of sites, plus total cancer mortality, in 35 European countries during the period 1990–1994. Trends in mortality are also given in graphical form for 24 major countries over the period 1955–1994. In most western European countries total cancer mortality was—for the first time—moderately downwards in the early 1990s. Such favourable trends included some decline in lung cancer mor...
131 CitationsSource
Cited By16
Abstract null null We report the case of a 55-year-old male patient with concomitant pulmonary mucinous adenocarcinoma and reactivated tuberculosis, documented with multiple MSCT (multi-slice computed tomography) changes. The patient initially presented with productive cough, sluggishness, fatigue, voice hoarseness and tuberculosis changes in MSCT. Later, he was diagnosed with pulmonary mucinous adenocarcinoma, which was confirmed by sputum cytology and transthoracic biopsy. Therefore, clinician...
#1Surbhi Dhadda (University of Rajasthan)
#2Ashok Kumar Raigar (University of Rajasthan)
Last. Anjali Guleria (University of Rajasthan)H-Index: 2
view all 5 authors...
Abstract null null According to World Health Organization Cancer is the second leading cause of death worldwide which accounted for an estimated 10.0 million deaths in 2020. Globally, the cancer burden is continuously growing, and it exerts tremendous physical, emotional, and financial strain on individuals, families, communities, and health systems. Looking at the stakes, researchers are vigorously trying to develop new anticancer agents. Recently, benzothiazole is emerging as one of the most a...
#1Anna WawruszakH-Index: 9
Last. Marta HalasaH-Index: 5
view all 6 authors...
Vorinostat (SAHA), an inhibitor of class I and II of histone deacetylases, is the first histone deacetylase inhibitor (HDI) approved for the treatment of cutaneous T-cell lymphoma in 2006. HDIs are promising anticancer agents that inhibit the proliferation of many types of cancer cells including breast carcinoma (BC). BC is a heterogeneous disease with variable biological behavior, morphological features, and response to therapy. Although significant progress in the treatment of BC has been made...
#1Sumaira AnjumH-Index: 10
Last. Christophe HanoH-Index: 22
view all 7 authors...
Cancer is regarded as one of the most deadly and mirthless diseases and it develops due to the uncontrolled proliferation of cells. To date, varieties of traditional medications and chemotherapies have been utilized to fight tumors. However, their immense drawbacks, such as reduced bioavailability, insufficient supply, and significant adverse effects, make their use limited. Nanotechnology has evolved rapidly in recent years and offers a wide spectrum of applications in the healthcare sectors. N...
#1Freddie Bray (IARC: International Agency for Research on Cancer)H-Index: 119
#2Mathieu Laversanne (IARC: International Agency for Research on Cancer)H-Index: 19
Last. Isabelle Soerjomataram (IARC: International Agency for Research on Cancer)H-Index: 50
view all 7 authors...
With the 2030 Sustainable Development Goals (SDG) target of a one-third reduction in noncommunicable diseases (NCDs) less than a decade away, it is timely to assess national progress in reducing premature deaths from the two leading causes of mortality worldwide. We examine trends in the probability of dying ages 30-70 from cardiovascular disease (CVD) and cancer 2000-19 in 10 middle-income (MICs) and 10 high-income (HICs) countries with high quality data. We then predict whether the SDG target ...
#1Zhixin Zhan (JLU: Jilin University)H-Index: 1
#2Ziqiang LiuH-Index: 1
Last. Haiyan HuangH-Index: 9
view all 6 authors...
#1Qicai Xiao (SYSU: Sun Yat-sen University)H-Index: 6
#2Xiao Dong (NUS: National University of Singapore)
Last. Shao Q. Yao (NUS: National University of Singapore)H-Index: 66
view all 8 authors...
Mitochondrion is a promising target in cancer therapy. However, gaining access to this organelle is difficult due to the obstacles to cross the complicated mitochondrial membrane. Cell-penetrating peptides (CPPs) with mitochondrion-targeting ability, named mitochondrion-targeting peptides (MTPs), are efficient tools to deliver exogenous therapeutics into mitochondria. Herein, we report several new MTPs, which can be readily synthesized via resin-based solid-phase peptide synthesis. In particular...
#1Islam ZakiH-Index: 3
Last. Ahmed S Saad (Port Said University)
view all 0 authors...
A new series of 2,4-disubstituted benzo[g]quinoxaline molecules have been synthesized, using naphthalene-2,3-diamine and 1,4-dibromonaphthalene-2,3-diamine as the key starting materials. The structures of the new compounds were confirmed by spectral data along with elemental microanalyses. The cytotoxic activity of all synthesized benzo[g]quinoxaline derivatives was assessed in vitro against the breast MCF-7 cancer cell line. The tested molecules revealed good cytotoxicity toward the breast MCF-...
#1Guillaume F. Combes (University of Split)
#2Ana-Marija Vučković (University of Split)
Last. Katarina Trajkovic (University of Split)H-Index: 8
view all 0 authors...
Cancer is one of the leading causes of premature death, and, as such, it can be prevented by developing strategies for early and accurate diagnosis. Cancer diagnostics has evolved from the macroscopic detection of malignant tissues to the fine analysis of tumor biomarkers using personalized medicine approaches. Recently, various nanomaterials have been introduced into the molecular diagnostics of cancer. This has resulted in a number of tumor biomarkers that have been detected in vitro and in vi...
#1Temidayo Fadelu (Harvard University)H-Index: 6
#2Timothy R. Rebbeck (Harvard University)H-Index: 107
1 CitationsSource